These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 10983735)

  • 1. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.
    Cazzola M; Donner CF
    Drugs; 2000 Aug; 60(2):307-20. PubMed ID: 10983735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
    Sovani MP; Whale CI; Tattersfield AE
    Drug Saf; 2004; 27(10):689-715. PubMed ID: 15350154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B; Markham A
    Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
    Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
    Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
    Holimon TD; Chafin CC; Self TH
    Drugs; 2001; 61(3):391-418. PubMed ID: 11293649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
    Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease.
    Sethi S; Cote C
    Curr Clin Pharmacol; 2011 Feb; 6(1):48-61. PubMed ID: 21235463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
    Reddy CB; Kanner RE
    Drugs Aging; 2007; 24(8):615-28. PubMed ID: 17702532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.
    Friedman M; Della Cioppa G; Kottakis J
    Pharmacotherapy; 2002 Sep; 22(9):1129-39. PubMed ID: 12222549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.
    Berger WE; Nadel JA
    Respir Med; 2008 Feb; 102(2):173-88. PubMed ID: 18023995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
    Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
    Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formoterol in the management of chronic obstructive pulmonary disease.
    Steiropoulos P; Tzouvelekis A; Bouros D
    Int J Chron Obstruct Pulmon Dis; 2008; 3(2):205-15. PubMed ID: 18686730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
    Cazzola M; Santangelo G; Piccolo A; Salzillo A; Matera MG; D'Amato G; Rossi F
    Pulm Pharmacol; 1994 Apr; 7(2):103-7. PubMed ID: 7915921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.
    Kankaanranta H; Harju T; Kilpeläinen M; Mazur W; Lehto JT; Katajisto M; Peisa T; Meinander T; Lehtimäki L
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):291-307. PubMed ID: 25515181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation.
    Appleton S; Poole P; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2002; (3):CD001104. PubMed ID: 12137617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchodilator therapy in chronic obstructive pulmonary disease.
    Manning HL
    Curr Opin Pulm Med; 2000 Mar; 6(2):99-103. PubMed ID: 10741767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators.
    Hanania NA; Donohue JF
    Proc Am Thorac Soc; 2007 Oct; 4(7):526-34. PubMed ID: 17878465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.